- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02209792
Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Five* Parallel Groups, Dose Finding Study of BIRB 796 BS (10, 20, 30, and 60 mg*) Administered Twice a Day Orally Over 8 Weeks in Patients With Moderate to Severe Crohn's Disease Followed by a 18 Weeks Treatment Extension in Patients With Clinical Remission or Clinical Response After 8 Weeks Treatment With the Respective Dose of BIRB 796 BS - Extension Phase. * Subsequent to Amendment 4 (Dated 11 Jun 2002) a 60 mg b.i.d. Group Was Included.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female patient of 18 to 65 years of age
- Provision of written informed consent in accordance with Good Clinical Practice and local legislation prior to any study procedures
- Diagnosis of Crohn's disease documented for at least 6 months. Preferably, inflammatory activity of the bowel should be confirmed by endoscopy within the last 3 months
- Moderate to severe Crohn's disease, CDAI ≥220 to ≤450, at baseline (visit 2)
Any of the following therapy, provided the respective criteria for dosage, duration and stability were satisfied:
- Prednisone or other systemic corticosteroids for at least 12 weeks with a stable oral dosage ≤25 mg/d or equivalent for at least two weeks prior to visit 2
- Budesonide with a stable dose of ≤ 9 mg/d for at least 2 weeks prior to visit 2 (changed by amendment 1, dated 16 January 2002)
- 5-Aminosalicylic Acid drugs/derivatives, provided they were given for 3 months or more and the dosage was stable for at least 4 weeks prior to visit 2
- 6-Mercaptopurine or azathioprine, provided they were taken for 6 months or more and the dosage was stable for at least 12 weeks prior to visit 2
- Methotrexate, provided it was taken for 6 months or more and the dosage was stable and ≤25 mg per week for at least 12 weeks prior to visit 2
The following patients were included in the 18-week treatment extension:
Patients who received BIRB 796 BS for 8 weeks and reached:
- Clinical remission (defined as CDAI <150) after 8 weeks or
- Clinical response (reduction of CDAI ≥70) after 8 weeks
- Patients who were willing to continue with their treatment
Exclusion Criteria:
- Pregnancy (to be excluded at visit 2 by urine β-human chorion-gonadotropin-test in women of childbearing potential) or breast feeding
- Female patients of childbearing potential (not 6 months post-menopausal or surgically sterilised) not using an approved form of birth control (hormonal contraceptives orally or in depot, intrauterine device)
- Patients without signs of inflammation of the bowel in the initial colonoscopy of the substudy
- Patients with colostomy or ileostomy
- Planned or needed surgery during the conduct of the trial due to Crohn's disease or for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage
- Known or suggested severe fixed symptomatic stenosis of the small or large intestine
- Severe underlying disease in particular of the GI tract (e.g. irritable bowel syndrome, celiac disease, infectious colitis)
- Patients with pathogens or Clostridium difficile toxin detected in the stool culture in the screening period
- Other infectious, ischemic, or immunological diseases with gastrointestinal involvement
- Patients with short bowel syndrome
- Patients who had had a treatment failure with a tumor necrosis factor (TNF)-blocking agent. Treatment failure was defined as not achieving a clinical response (improvement of ≥70 points in CDAI within 4 weeks) in a clinical trial or - in clinical practice -discontinuation of the TNF-blocking agent due to ineffectiveness (changed according to amendment 1, dated 16 January 2002)
- Treatment with cyclosporine A within 12 weeks prior to visit 2
Last dose given within the specified time period before visit 2 for the following compounds:
- infliximab (Remicade®): 8 weeks,
- investigational agent: 4 weeks or 5 half-lives, whichever is longer
- Treatment with anti-inflammatory medication deviating from the criteria for dosage, and stability as provided in the inclusion criteria
Patients treated with any of the following therapy:
- antibiotics provided the dosage had not been stable within 2 weeks prior to visit 2;
- parenteral or elemental diet;
- intrarectal therapy for Crohn's disease 2 weeks prior to visit 2 (added by amendment 1, dated 16 January 2002)
Treatment with:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to visit 2;
- Acetylsalicylic acid >100 mg/d;
- Paracetamol (acetaminophen) >3 g/day;
- Drug classified as proton pump inhibitor: 7 days prior to visit 2. This exclusion criterion was deleted after amendment 2 dated 11 June 2002.
- Drug classified as H2-receptor-blocker or antacid: 2 days prior to visit 2. This exclusion criterion was deleted after amendment 2 dated 11 June 2002.
- Active infection or serious infectious diseases resulting in hospitalisation or requiring systemic anti-infective therapy within 4 weeks before visit 2
- Serologic evidence of active hepatitis B and/or C
- Known HIV-infection
- History of prior tuberculosis infection or suspicion of active infection at screening based on chest X-ray done within 6 months prior to treatment phase
- History of cardiovascular, renal, neurologic, psychiatric, liver, immunologic, or endocrine dysfunction if they were clinically significant. A clinically significant disease was defined as one which, in the opinion of the investigator, may have either put the patient at risk because of participation in the study or as a disease which may have influenced the results of the study or the patient's ability to participate in the study
- Recent history of heart failure (one year or less) or myocardial infarction or patients with any cardiac arrhythmia requiring drug therapy (changed by amendment 1, dated 16 January 2002)
- ECG results outside of the reference range of clinical relevance including, but not limited to QTcB >480 msec, PR interval >240 msec, QRS interval >110 msec
- History of malignant disease in the last 5 years or suspicion of active malignant disease except successfully treated squamous or basal cell carcinoma of the skin and except patients with cervical carcinoma in situ who have had adequate treatment and follow up
- Clinically significant abnormal baseline haematology, blood chemistry or urinalysis if the abnormality defines a disease listed as an exclusion criterion
Any of the following specific laboratory abnormalities at visit 1:
- alanine aminotransferase (ALT), aspartate aminotransferase (AST) greater than upper limit of normal range (ULN)
- Total bilirubin greater than ULN except for patients with documented Gilbert's disease
- Gamma-glutamyltransferase, alkaline phosphatase or lactate dehydrogenase greater than 1.5 x ULN
- White blood cell count greater than 1.5 ULN which was not due to Crohn's disease as assessed by the investigator
- Serum creatinine above 1.5 x ULN
- History of drug or alcohol abuse within the past two years or active drug or alcohol abuse
- Participation in another clinical trial within 4 weeks or 5 half-lives of the respective investigational agent, whichever was longer
- Hypersensitivity to trial drug
- Inability to comply with the protocol
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador de Placebo: Placebo
|
|
Experimental: BIRB 796 BS, low dose
2 x 5 mg b.i.d.
|
|
Experimental: BIRB 796 BS, medium dose 1
20 mg b.i.d.
|
|
Experimental: BIRB 796 BS, medium dose 2
2 x 5 mg + 20 mg b.i.d.
|
|
Experimental: BIRB 796 BS, high dose
3 x 20 mg b.i.d.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Clinical Remission defined as Crohn's Disease Activity Index (CDAI) < 150
Prazo: at week 8
|
at week 8
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Clinical remission (defined as a CDAI score below 150)
Prazo: at week 26
|
at week 26
|
|
Stabilised clinical remission at the end of the main treatment phase
Prazo: at week 8 and 10
|
at week 8 and 10
|
|
Time to clinical remission
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Duration of maintenance of clinical remission
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Clinical response (defined as a reduction of CDAI score ≥70)
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Time to clinical response
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Duration of maintenance of clinical response
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Changes from baseline in the CDAI score
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Changes from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) score
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Number of patients with 50% fistulae reduction
Prazo: up to 26 weeks
|
defined as an at least 50% reduction from baseline in the number of draining fistulae
|
up to 26 weeks
|
Changes from baseline in the number of draining fistulae
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Changes from baseline in C-reactive protein (CRP) measurements
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Changes from baseline in the daily corticosteroid dose
Prazo: after week 10
|
measured in mg prednisone equivalent
|
after week 10
|
Number of drop-outs due to treatment failure
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Number of patients with adverse events
Prazo: up to 40 weeks
|
up to 40 weeks
|
|
Number of patients with clinically relevant changes in laboratory parameters
Prazo: up to week 38
|
up to week 38
|
|
Number of patients with relevant findings in electrocardiogram (ECG)
Prazo: up to 26 weeks
|
up to 26 weeks
|
|
Extended clinical response (defined as a reduction of CDAI score ≥ 100)
Prazo: week 10 to 26
|
week 10 to 26
|
|
Time to extended clinical response
Prazo: week 10 to 26
|
week 10 to 26
|
|
Duration of maintenance of extended clinical response
Prazo: week 10 to 26
|
week 10 to 26
|
|
Changes from baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) score
Prazo: at the end of week 8
|
for patients in the endoscopic substudy only
|
at the end of week 8
|
Changes from baseline in the histological scoring of biopsy specimens
Prazo: at the end of week 8
|
for patients in the endoscopic substudy only
|
at the end of week 8
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1175.12
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doença de Crohn
-
ProgenaBiomeRecrutamentoDoença de Crohn | Colite de Crohn | Ileocolite de Crohn | Gastrite de Crohn | Jejunite de Crohn | Duodenite de Crohn | Esofagite de Crohn | Doença de crohn | Doença de Crohn do Íleo | Ileíte de Crohn | Recaída da Doença de Crohn | Doença de Crohn agravada | Doença de Crohn em remissão | Doença de Crohn do PiloroEstados Unidos
-
Massachusetts General HospitalAmerican College of GastroenterologyAinda não está recrutandoDoenças Inflamatórias Intestinais | Doença de Crohn | Colite de Crohn | Ileocolite de Crohn | Gastrite de Crohn | Jejunite de Crohn | Duodenite de Crohn | Esofagite de CrohnEstados Unidos
-
Janssen-Cilag Ltd.RecrutamentoDoença de Crohn Fistulizante | Doença Perianal de CrohnHolanda, Estados Unidos, Bélgica, Republica da Coréia, Taiwan, Israel, Japão, Canadá, Hungria, Alemanha, Grécia, Reino Unido, Austrália, Espanha, Arábia Saudita, Polônia, Peru, Portugal, Tcheca, Itália, Jordânia, França
-
Groupe Hospitalier Paris Saint JosephConcluído
-
ViomeAtivo, não recrutandoDoença de Crohn | Colite ulcerativa | Doença de Crohn agravada | Doença de Crohn em remissão | Intestino irritávelEstados Unidos
-
University of Rome Tor VergataDesconhecidoDoença de Crohn | Ileocolite de CrohnItália
-
University Hospital, LilleInstitut National de la Santé Et de la Recherche Médicale, France; National...ConcluídoIleocolite de CrohnFrança
-
Richard Burt, MDRescindidoDOENÇA DE CROHNEstados Unidos
-
Agomab Spain S.L.RecrutamentoDoença de Crohn FibroestenóticaEstados Unidos, Itália, Polônia, Espanha, Dinamarca, Áustria, Canadá, Alemanha